Log In Sign up
The largest database of trusted experimental protocols

Cd62l bv510

Manufactured by BioLegend
Visit Supplier

CD62L-BV510 is a fluorochrome-conjugated antibody specific for the CD62L cell surface marker. CD62L is also known as L-selectin, which plays a role in lymphocyte homing and migration. The BV510 fluorochrome allows for detection and analysis of CD62L-expressing cells using flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Cd44 fitc, by BioLegend (1 mentions) Cd8 fitc, by BioLegend (1 mentions) Lag3 bv785, by BioLegend (1 mentions) Tim3 apc fire750, by BioLegend (1 mentions) Cd90.2 buv395, by BD (1 mentions) Cd4 buv496, by BD (1 mentions) Nk1.1buv661, by BD (1 mentions) Cd8 buv805, by BD (1 mentions) Cd62l bv605, by BD (1 mentions) Cd4 apc cy7, by BioLegend (1 mentions) Cd3 apc, by BioLegend (1 mentions) Cd4 pe cy7, by BioLegend (1 mentions) Cd56 pe cy7, by BioLegend (1 mentions) Cd38 pe cy7, by BioLegend (1 mentions) Cd8 pacific blue, by BioLegend (1 mentions) 7 aad, by BioLegend (1 mentions) Cd10 apc, by BioLegend (1 mentions) Cd19 apc cy7, by BioLegend (1 mentions) Cd62l pe, by BD (1 mentions) Cd22 pe, by BioLegend (1 mentions)

Close spelling variants of this product

CD62L (93 citations) CD62L-BV510 (MEL-14, (3 citations)

2 protocols using cd62l bv510

1

Multiparameter Flow Cytometry for Immune Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fluorochrome-conjugated antibodies were used to select and sort cell subsets, analyze T cell phenotypes, and to determine cytokine production. The following antibodies were used in this study, separated by manufacturer (clone is indicated in parentheses). Biolegend: Ki67-PacificBlue (16A8), CD62L-BV510 (MEL-14), CD73-BV605 (TY/11.8), CD44-FITC (IM7), PD1-PEDazzle594 (RMP1–30), TIGIT-PECy7 (1G9), LAG3-BV785 (C9B7W), IFNγ (XMG1.2), TNFα-PECy7 (MP6-XT22), SATB1-AlexaFluor594 (O96C6), TIM3-APC/Fire750 (B8.2C12), OX40-BV711 (OX-86), OX40L-PECy7 (RM134L), Tim3-PerCP/Cy5.5 (B8.2C12), CD8-FITC (53–6.7), CD90.2-PECy7 (30H12), CD90.2-PerCP/Cy5 (53–2.1), CD4-APCCy7 (RM4–5). || BD Biosciences: CD90.2-BUV395 (53–2.1), CD4-BUV496 (GK1.5), CD19-BUV661 (1D3), CD11c-BUV661 (N418), F4/80-BUV661 (T45–2342), NK1.1BUV661 (PK136), TER119-BUV661 (TER-119), CD127-BUV737 (SB/199), CD8-BUV805 (53–6.7), FR4-BV421 (12A5), CTLA4-APCR700 (UC10–4F10–11), NK1.1-eFluor450 (PK136), Ter-119-eFluor450 (Ter119), Rorγt-BV650 (Q31–378), CD62L-BV605 (MEL-14). || Invitrogen: FoxP3-AlexaFluor532 (FJK-16s), CD44-BUV737 (IM7), PD1-SB780 (J43), TOX-eFluor660 (TXRX10), EOMES-PerCP/eFluor710 (Dan11mag), F4/80-eFluor450 (BM8), CD49b-eFluor450 (DX5), CD11c-eFluor450 (N418), PD1-PerCPe710 (J43). || Santa Cruz Biotechnologies: NFATc1-AlexaFluor488 (7A6), CD30L-AlexaFluor680 (RM153).
Pollard J., Hynes G., Yin D., Mandal M., Gounari F., Alegre M.L, & Chong A. (2023). Pregnancy programs epigenetic and transcriptional exhaustion in memory CD8+ T cells. Research Square.
+ Open protocol
+ Expand
2

Comprehensive Immunophenotyping of Tumor and T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tumor cells and T cells were phenotyping with CD3‐APC (OKT3, UCH1), CD19‐APC CY7 (SJ26C1), CD4‐PE Cy7 (RPA‐T4, A161A1), CD8‐pacific blue (RPA‐T8, SK1), CD10‐APC (HI10a), CD22‐PE (HIB22), CD38‐PECy7 (HTT2), CD56‐PE CY7 (MEM‐188), CD62L‐BV510 (DREG‐56), PDL1‐PE (29E.2A3), PD1‐FITC (EH12.2H7), streptavidin‐APC‐Cy7, and 7AAD, which were purchased from BioLegend. CD20‐FITC (2H7), CD45RA‐FITC (HI100), and CD62L‐PE (DREG‐56) were purchased from BD. CD137‐PE, CD34‐APC, and antibiotin‐PE were purchased from MACS. The percentage of CAR‐CD19 was determined by biotinylated Erbitux. All cells were analyzed MACSquant with a filter set for eight fluorescence signals and analyzed with FlowJo software (Tree Star).
Ma F., Ho J., Du H., Xuan F., Wu X., Wang Q., Wang L., Liu Y., Ba M., Wang Y., Luo J, & Li J. (2019). Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematological Oncology, 37(5), 601-608.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!